Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer
Emmaus Life Sciences (OTCMarkets: EMMA), a leader in sickle cell disease treatment, has appointed Willis C. Lee as its new Chief Executive Officer. Lee, previously serving as Co-President and Chief Operating Officer, will retain his position as Chairman of the Board. The company is focusing on improving operational efficiency and preparing for challenges posed by the launch of generic L-glutamine.
Lee emphasized plans to grow market presence in the Middle East and invest in research to expand pipelines and increase company value. He committed to working closely with the Board, restructured teams, and stakeholders to justify their trust in the company's future.
Emmaus Life Sciences (OTCMarkets: EMMA), leader nel trattamento della malattia falciforme, ha nominato Willis C. Lee come nuovo Amministratore Delegato. Lee, che in precedenza ricopriva il ruolo di Co-Presidente e Direttore Operativo, manterrà anche la sua posizione di Presidente del Consiglio di Amministrazione. L'azienda si concentra su migliorare l'efficienza operativa e prepararsi alle sfide poste dal lancio del L-glutamina generico.
Lee ha sottolineato i piani per ampliare la presenza nel mercato del Medio Oriente e investire nella ricerca per diversificare le pipeline e aumentare il valore dell'azienda. Si è impegnato a collaborare strettamente con il Consiglio, i team ristrutturati e le parti interessate per giustificare la loro fiducia nel futuro dell'azienda.
Emmaus Life Sciences (OTCMarkets: EMMA), líder en el tratamiento de la enfermedad de células falciformes, ha nombrado a Willis C. Lee como su nuevo Director Ejecutivo. Lee, que anteriormente se desempeñaba como Co-Presidente y Director de Operaciones, mantendrá su cargo como Presidente de la Junta. La empresa se centra en mejorar la eficiencia operativa y prepararse para los desafíos que plantea el lanzamiento de L-glutamina genérica.
Lee enfatizó los planes de incrementar la presencia en el mercado de Medio Oriente e invertir en investigación para expandir las carteras y aumentar el valor de la empresa. Se comprometió a trabajar en estrecha colaboración con la Junta, equipos reestructurados y partes interesadas para justificar su confianza en el futuro de la empresa.
엠마우스 생명과학 (OTCMarkets: EMMA)는 겸상적혈구질환 치료의 선두주자로서 윌리스 C. 리를 새 CEO로 임명했습니다. 리는 이전에 공동 사장 및 COO로 재직하였으며, 이사회 의장직도 유지할 것입니다. 이 회사는 운영 효율성 개선과 일반 L-글루타민 출시로 인한 도전과제 준비에 집중하고 있습니다.
리 회장은 중동 시장에서의 존재감 확대 및 연구 투자를 통해 제품 파이프라인을 확장하고 회사 가치를 증가시키겠다는 계획을 강조했습니다. 그는 이사회, 재구성된 팀과 이해관계자와 긴밀히 협력하여 회사의 미래에 대한 신뢰를 정당화하겠다고 약속했습니다.
Emmaus Life Sciences (OTCMarkets: EMMA), leader dans le traitement de la drépanocytose, a nommé Willis C. Lee comme nouveau PDG. Lee, qui a précédemment exercé les fonctions de Co-Président et de Directeur des Opérations, conservera également son rôle de Président du Conseil d'Administration. L'entreprise se concentre sur l'amélioration de l'efficacité opérationnelle et la préparation aux défis posés par le lancement de la L-glutamine générique.
Lee a souligné les projets d'accroître la présence sur le marché du Moyen-Orient et d'investir dans la recherche pour élargir les pipelines et augmenter la valeur de l'entreprise. Il s'est engagé à travailler en étroite collaboration avec le Conseil, les équipes restructurées et les parties prenantes pour justifier leur confiance dans l'avenir de l'entreprise.
Emmaus Life Sciences (OTCMarkets: EMMA), führend in der Behandlung von Sichelzellenanämie, hat Willis C. Lee zum neuen CEO ernannt. Lee, der zuvor als Co-Präsident und COO tätig war, wird auch weiterhin als Vorsitzender des Vorstands fungieren. Das Unternehmen konzentriert sich auf die Verbesserung der operativen Effizienz und die Vorbereitung auf die Herausforderungen, die mit der Markteinführung von generischem L-Glutamin verbunden sind.
Lee betonte die Pläne, die Marktpräsenz im Nahen Osten auszubauen und in Forschung zu investieren, um die Produktpipeline zu erweitern und den Unternehmenswert zu steigern. Er verpflichtete sich, eng mit dem Vorstand, umstrukturierten Teams und Stakeholdern zusammenzuarbeiten, um deren Vertrauen in die Zukunft des Unternehmens zu rechtfertigen.
- Appointment of experienced executive Willis C. Lee as CEO
- Focus on improving operational efficiency
- Plans to expand market presence in the Middle East
- Commitment to invest in research for pipeline expansion
- Potential challenges from the launch of generic L-glutamine
- Need for company-wide reorganization suggests previous inefficiencies
Mr. Lee said, "we are working hard to improve the efficiency of the company by reorganizing every level of our operations. We believe that these moves will better position us to serve our patients, clients, and shareholders, and equip us to face the challenges posed by the launch of generic L-glutamine. As the new CEO, I will ensure that we continue to grow our market presence in the
About Emmaus Life Sciences
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sale of innovative treatments and therapies, including those in the rare and orphan disease categories. For more information, please visit www.emmausmedical.com.
Forward-looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time, including uncertainties related to Emmaus' working capital and ability to carry on its existing operations and obtain needed financing and other factors previously disclosed in the company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on July 3, 2024, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.
Company Contact:
Emmaus Life Sciences, Inc.
Investor Relations
(310) 214-0065
IR@emmauslifesciences.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/emmaus-life-sciences-announces-willis-c-lee-as-chief-executive-officer-302203675.html
SOURCE Emmaus Life Sciences, Inc.
FAQ
Who is the new CEO of Emmaus Life Sciences (EMMA)?
What was Willis C. Lee's previous role at Emmaus Life Sciences (EMMA)?
What are the main challenges facing Emmaus Life Sciences (EMMA) according to the July 23, 2024 announcement?
What are the key strategic focuses for Emmaus Life Sciences (EMMA) under the new CEO?
